A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with metastatic castration-resistant prostate cancer
Patrice Olson
Advertisement
Articles by Patrice Olson
A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival and progression-free survival in favor of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer
Co-targeting metastatic castrate resistant prostate cancer with the combination of enzalutamide plus abiraterone acetate may circumvent the compensatory mechanisms observed with either agent alone and lead to more profound suppression of androgen signaling.
Advertisement
Latest Updated Articles
Enzalutamide Plus Abiraterone May Have Higher Response Rate in mCRPC Than Either Agent AlonePublished: October 1st 2013 | Updated:
Additional OS and PFS Benefits Seen With Aflibercept in Post-Hoc VELOUR AnalysisPublished: October 1st 2013 | Updated:
Biomarkers Predict Prognosis for Patients With mCRPCPublished: October 3rd 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5